Ventas, Inc. $VTR Shares Sold by Engineers Gate Manager LP

Engineers Gate Manager LP lessened its position in Ventas, Inc. (NYSE:VTR) by 72.2% during the second quarter, Holdings Channel reports. The institutional investor owned 206,146 shares of the real estate investment trust’s stock after selling 536,068 shares during the quarter. Engineers Gate Manager LP’s holdings in Ventas were worth $18,306,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Dynamic Wealth Strategies LLC bought a new position in Ventas during the first quarter valued at about $25,000. Wiser Advisor Group LLC acquired a new stake in Ventas in the 3rd quarter valued at about $27,000. Silvant Capital Management LLC acquired a new stake in Ventas in the 2nd quarter valued at about $28,000. Meeder Asset Management Inc. bought a new position in shares of Ventas during the 2nd quarter valued at about $30,000. Finally, IFC & Insurance Marketing Inc. bought a new position in shares of Ventas during the 4th quarter valued at about $30,000. Institutional investors and hedge funds own 94.18% of the company’s stock.

Ventas Stock Performance

Shares of Ventas stock opened at $89.37 on Thursday. Ventas, Inc. has a 12 month low of $66.54 and a 12 month high of $101.60. The company has a quick ratio of 0.44, a current ratio of 0.44 and a debt-to-equity ratio of 0.86. The stock has a market cap of $45.84 billion, a PE ratio of 165.49, a price-to-earnings-growth ratio of 3.51 and a beta of 0.70. The business has a fifty day simple moving average of $92.98 and a 200-day simple moving average of $87.92.

Ventas (NYSE:VTR) last posted its quarterly earnings results on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.73 billion for the quarter, compared to analyst estimates of $1.68 billion. Ventas had a return on equity of 1.99% and a net margin of 4.08%.Ventas’s quarterly revenue was up 21.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 earnings per share. On average, sell-side analysts anticipate that Ventas, Inc. will post 3.89 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on VTR shares. Mizuho boosted their target price on shares of Ventas from $98.00 to $104.00 and gave the stock an “outperform” rating in a report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $100.00 target price on shares of Ventas in a report on Tuesday, June 16th. Raymond James Financial started coverage on Ventas in a report on Tuesday, June 16th. They issued an “outperform” rating and a $94.00 price target on the stock. Scotiabank raised their price objective on Ventas from $93.00 to $95.00 and gave the stock a “sector perform” rating in a research note on Wednesday, September 2nd. Finally, BMO Capital Markets lifted their target price on Ventas from $105.00 to $107.00 and gave the stock an “outperform” rating in a report on Tuesday, August 11th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.00.

Ventas Company Profile

Ventas, Inc is a real estate investment trust (REIT) that owns and manages a diversified portfolio of healthcare and senior living properties. Its real estate platform includes senior housing communities, medical office buildings, life science and innovation centers, and other healthcare-related facilities.

The company generally leases or operates its properties through relationships with healthcare providers, senior living operators, universities, and research institutions. Its properties support services such as independent and assisted living, skilled nursing, outpatient care, physician practices, medical research, and biotechnology development.

Ventas serves major healthcare and life science markets in the United States and Canada.